

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BICARA THERAPEUTICS, INC.,
Petitioner,

v.

THE JOHNS HOPKINS UNIVERSITY,
Patent Owner.

PGR2026-00025
Patent 12,295,968

DECLARATION OF RYAN COHLHEPP, PHARM.D.

PGR2026-00025

U.S. Patent No. 12,295,968

I, Ryan Cohlhepp, Pharm.D., hereby declare as follows:

1. I am President and Chief Operating Officer of Bicara Therapeutics, Inc. (“Bicara”). I am also a member of Bicara’s board of directors (the “Board”). I have prepared this declaration based on my personal knowledge, information I have collected and reviewed, and discussions with Bicara’s employees who are knowledgeable about the finances, preparation, and management of Bicara’s Petition for Post-Grant Review of U.S. Patent No. 12,295,968 (“’968 Patent”) in PGR2026-00025 (“PGR”).
2. I have served as President and Chief Operating Officer at Bicara since October 2020. I have served as a member of Bicara’s Board since August 2024 and previously from December 2020 to March 2023.
3. Bicara is a U.S., clinical-stage, biopharmaceutical company developing bifunctional therapeutics for the treatment of solid tumors. Bicara’s lead investigational therapy is ficerafusp alfa (also known as BCA101), a bifunctional EGFR (epidermal growth factor receptor) / TGF- β (transforming growth factor beta) antibody currently in clinical development.
4. Bicara’s principal place of business and corporate headquarters are located at 116 Huntington Avenue, Suite 703, Boston, Massachusetts 02116.
5. Bicara currently has approximately 100 full-time employees—over 90% of whom are based in the United States.

PGR2026-00025

U.S. Patent No. 12,295,968

6. Bicara is a Delaware corporation. Bicara was incorporated under the laws of the State of Delaware in December 2018 as a wholly-owned subsidiary of Biocon Ltd. (“Biocon”). EX1096 (Biocon 2019 Annual Report) at 13, 108, 122.

7. By 2021, Bicara began operating as a standalone company under independent management after Biocon ceded control to Bicara’s Board and management. EX1097 (Biocon 2021 Annual Report) at 15.

8. Prior to its initial public offering, Bicara raised funds through multiple rounds of stock sales in 2022 and 2023, including stock sales to independent investors. Throughout these financings, investors invested over \$300 million in Bicara.

9. Bicara completed its initial public offering in September 2024, raising approximately \$362 million in gross proceeds from investors. In September 2024, Bicara became a publicly-traded company on the Nasdaq Global Market under the ticker symbol “BCAX.” Bicara has operated as a publicly-traded company since. The Nasdaq Global Market, located in New York City, is the only public market in the world on which Bicara is listed.

10. In February 2026, Bicara completed a follow-on public offering, raising approximately \$172.5 million in gross proceeds from investors.

11. As of March 31, 2026, Bicara has raised an additional \$29.5 million in net proceeds through an “at-the-market” program.

PGR2026-00025

U.S. Patent No. 12,295,968

12. Bicara operates independently from Biocon. Bicara has its own executive leadership team, its own Board, its own employees, its own management structure, and its own in-house legal function.

13. From the issuance of the '968 Patent on May 13, 2025 through to the present, Bicara's Board has had 10 directors. They are:

- i. Michael Powell, Ph.D., Director (Chairperson of the Board);
- ii. Claire Mazumdar, Ph.D., M.B.A., CEO and Director;
- iii. Ryan Cohlhepp, Pharm.D., President, COO, and Director;
- iv. Christopher Bowden, M.D., Director;
- v. Kate Haviland, M.B.A., Director;
- vi. Nils Lonberg, Ph.D., Director;
- vii. Kiran Mazumdar-Shaw, Director;
- viii. Carolyn Ng, Ph.D., Director;
- ix. Scott Robertson, Director (Chair of Audit Committee); and
- x. Jake Simson, Director.

14. Kiran Mazumdar-Shaw serves as a member of Bicara's Board and has served in that capacity since December 2018. Bicara's Board has determined that Ms. Mazumdar-Shaw is an independent director, including for purposes of the rules of Nasdaq and the SEC. Ms. Mazumdar-Shaw holds no other positions at Bicara and has not held any other positions at Bicara between the issuance of the '968 Patent on May 13, 2025 and the present.

PGR2026-00025

U.S. Patent No. 12,295,968

15. Apart from Kiran Mazumdar-Shaw's service as a non-employee director on Bicara's Board, no officer, director, employee, or representative of Biocon or any Biocon-affiliated entity has served as an executive officer or director of Bicara between the issuance of the '968 Patent on May 13, 2025 to the present.

16. Bicara funds, controls, and directs this PGR. Bicara brought this PGR for its benefit and on behalf of its interests. Bicara independently desired review of the '968 Patent and independently authorized, funded, and directed the filing and continued litigation of this PGR.

17. Bicara's employees and executive officers made the decision to bring this PGR. The decision to bring this PGR was not subject to a vote by Bicara's Board nor subject to stockholder approval.

18. Strategy decisions in this proceeding, including decisions regarding grounds, expert selection, and litigation strategy, have been made by Bicara in consultation with its outside counsel retained by Bicara.

19. Bicara has provided all of the funding for fees associated with the preparation, filing, and continued litigation of this PGR.

20. Kiran Mazumdar-Shaw has not funded, controlled, or directed this PGR.

21. Neither Biocon nor any Biocon-affiliated entity has funded, controlled, or directed this PGR.


PGR2026-00025

U.S. Patent No. 12,295,968

22. No employee or representative of Biocon or any Biocon-affiliated entity participated in the drafting of this PGR petition. No employee or representative of Biocon or any Biocon-affiliated entity reviewed any drafts of the PGR petition before it was filed.

I declare under penalty of perjury under the laws of the United States of America that, to the best of my knowledge, the foregoing is true and correct. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Executed: 5/17/2026

By: /  /
Ryan Cohlhepp, Pharm.D.